In a patient with chronic kidney disease and a family history of renal disease, how can I differentiate Autosomal Dominant Polycystic Kidney Disease (ADPKD) from Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differentiating ADPKD from ADTKD

The key distinction is imaging: ADPKD presents with massively enlarged kidneys filled with numerous bilateral cysts visible on ultrasound, whereas ADTKD shows normal-sized or small kidneys with minimal or absent cysts, bland urinary sediment, and minimal proteinuria. 1, 2

Imaging Characteristics

ADPKD Features

  • Bilaterally enlarged kidneys with multiple cysts throughout both cortex and medulla 3, 4
  • Cysts increase progressively in size and number with age 3
  • Liver cysts frequently present as an extrarenal manifestation 4
  • Diagnosis in at-risk adults aged 15-39 requires ≥3 total renal cysts; aged 40-59 requires ≥2 cysts in each kidney 4

ADTKD Features

  • Normal-sized or small kidneys with increased echogenicity 2, 5
  • Cysts are absent or minimal, appearing only in advanced disease stages and not causing GFR decline 1, 2
  • When present, cysts are non-medullary and do not increase with age like ADPKD 2
  • Kidney size declines as disease progresses 1

Laboratory Differentiation

ADPKD Pattern

  • Variable proteinuria, often more than minimal 6
  • Hematuria common, including macroscopic episodes 4
  • Hyperuricemia not a defining feature 7

ADTKD Pattern

  • Bland urinary sediment with absent or minimal proteinuria (<1 g/day) 1, 2
  • Microscopic hematuria only occasionally present 1
  • Hyperuricemia with fractional urate excretion <5% highly characteristic of ADTKD-UMOD subtype 2, 5, 7
  • Early-onset gout (often teenage years in males) suggests ADTKD-UMOD 2, 5
  • Hypomagnesemia and hypokalemia point toward ADTKD-HNF1B 2

Clinical Presentation Patterns

ADPKD

  • Flank or abdominal pain common 4
  • Macroscopic hematuria episodes 4
  • Hypertension develops early, often before significant GFR loss 6
  • ESRD typically after age 50-60 in PKD1, later in PKD2 3

ADTKD

  • Absence of severe hypertension in early disease; only modest elevation as CKD advances 1, 2
  • Minimal symptoms until advanced CKD 1
  • ESRD typically between ages 30-50 (range 20-80 years) 1, 2
  • Childhood anemia resolving at puberty suggests ADTKD-REN 2

Family History Clues

ADPKD

  • Clear autosomal dominant pattern with affected individuals in multiple generations 4
  • Penetrance nearly 100% by age 60 6
  • Symmetric disease severity within families 4

ADTKD

  • Autosomal dominant pattern but may appear sporadic due to variable expressivity, early death of relatives, or misdiagnosis 1, 2
  • Three-generation pedigree showing unexplained CKD, early-onset gout (before age 40), childhood anemia, MODY5 diabetes, or dialysis before age 60 strongly suggests ADTKD 2
  • De novo mutations occur, particularly in HNF1B 1

Extrarenal Manifestations

ADPKD

  • Hepatic cysts in majority of patients 4, 6
  • Intracranial aneurysms in 5-10% 6
  • Cardiac valve abnormalities 6

ADTKD-HNF1B Specifically

  • MODY5-type diabetes 1, 2
  • Genital tract anomalies 2
  • Pancreatic atrophy or hypoplasia 2
  • Abnormal liver function tests 2

Histopathology (When Biopsy Performed)

ADPKD

  • Cyst-lined epithelium with focal cyst formation 6
  • Relatively preserved intervening parenchyma until late disease 6

ADTKD

  • Interstitial fibrosis with tubular atrophy as primary finding 1, 2
  • Thickened, lamellated tubular basement membranes 1, 2
  • Negative immunofluorescence for complement and immunoglobulins 1, 2
  • UMOD subtype: intracellular uromodulin deposits in thick ascending limb cells 2

Diagnostic Algorithm

  1. Obtain renal ultrasound as first-line imaging 2

    • Massively enlarged kidneys with numerous bilateral cysts → ADPKD 3, 4
    • Normal or small kidneys with minimal/no cysts → consider ADTKD 2, 5
  2. Assess urinalysis and proteinuria 2

    • Active sediment with significant proteinuria → less likely ADTKD 2
    • Bland sediment with <1 g/day proteinuria → ADTKD pattern 2
  3. Check serum uric acid and fractional urate excretion 2, 7

    • Fractional excretion <5% with hyperuricemia → strongly suggests ADTKD-UMOD 2, 5
  4. Evaluate three-generation pedigree for unexplained CKD, early gout, childhood anemia, MODY5 diabetes 2

  5. Consider genetic testing when ADTKD suspected: sequence UMOD and MUC1 first (most common), add HNF1B if extrarenal features present, include REN if childhood anemia documented 2, 8, 9

Common Pitfalls

  • Do not assume all inherited cystic kidney disease is ADPKD; ADTKD can have occasional cysts in advanced stages but presents fundamentally differently 1
  • Do not exclude ADTKD based on negative family history; affected relatives may have died young, been misdiagnosed, or the patient may have a de novo mutation 1, 2
  • Do not rely on presence/absence of hyperuricemia alone; while characteristic of ADTKD-UMOD, it is not universal across all ADTKD subtypes 2, 9
  • ADTKD is significantly underdiagnosed; it represents 1% of CKD stages 3-5 patients and is the most common genetic kidney disease after ADPKD 9

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Work‑Up for Tubulointerstitial Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Clinical diagnosis of Autosomal Dominant Polycystic Kidney Disease].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2016

Guideline

Kidney Size Assessment in Gout‑Related Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Uric Acid and Gouty Nephropathy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.